Cannabis: multigenerational and food chain impacts.
Saved in:
| Title: | Cannabis: multigenerational and food chain impacts. |
|---|---|
| Authors: | Reece, Albert Stuart (AUTHOR), Hulse, Gary Kenneth (AUTHOR) |
| Source: | European Archives of Psychiatry & Clinical Neuroscience. Oct2025, Vol. 275 Issue 7, p2189-2191. 3p. |
| Abstract: | The article discusses the potential risks and limitations of cannabinoid use in medical applications, emphasizing that alternative treatments may be more effective and better tolerated for conditions such as refractory childhood epilepsy, pain, and multiple sclerosis spasticity. It highlights concerns regarding the mental health impacts of cannabis, including its association with major mental illnesses and cognitive decline, as well as its potential to cause congenital anomalies and other health issues through epigenetic and genomic disruptions. The authors argue that current regulations do not adequately address the broad implications of cannabinoid exposure, particularly in relation to environmental contamination and intergenerational health effects. Overall, the article calls for a reevaluation of the perceived benefits of cannabinoids in light of these significant risks. [Extracted from the article] |
| Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The article discusses the potential risks and limitations of cannabinoid use in medical applications, emphasizing that alternative treatments may be more effective and better tolerated for conditions such as refractory childhood epilepsy, pain, and multiple sclerosis spasticity. It highlights concerns regarding the mental health impacts of cannabis, including its association with major mental illnesses and cognitive decline, as well as its potential to cause congenital anomalies and other health issues through epigenetic and genomic disruptions. The authors argue that current regulations do not adequately address the broad implications of cannabinoid exposure, particularly in relation to environmental contamination and intergenerational health effects. Overall, the article calls for a reevaluation of the perceived benefits of cannabinoids in light of these significant risks. [Extracted from the article] |
|---|---|
| ISSN: | 09401334 |
| DOI: | 10.1007/s00406-025-02003-1 |
